Dr. Silverstone 's research
interests include the medical
treatment of glaucoma,
the role of anti-inflammatory
medications in post-surgical
patient management, the
development of imaging
devices for diagnosing
and managing glaucoma,
and the computerization of
medical records.
|
David E. Silverstone, M.D.,
founded Temple Eye Physicians in 1977, which merged with
Ophthalmic Surgical Associates in 2001 to form The Eye Care Group. He specializes
in cataract and lens implant microsurgery and glaucoma
and is board-certified by the American Board of Ophthalmology.
Dr. Silverstone received his undergraduate degree from
Columbia College and his medical degree from New York
Medical College. He completed his ophthalmology residency, a
glaucoma research fellowship, and a chief residency at Yale.
He did a fellowship in Intraocular Lens Implantation at New
York Medical College.
Dr. Silverstone is a Clinical Professor and Assistant
Chief of Ophthalmology at Yale. He has served as the Chief of ophthalmology
at the West Haven VA Hospital and is on staff at the Temple Surgical Center
and the Hospital of Saint Raphael.
He was part of the Yale team that developed Timolol, the first modern
medication for the treatment
of glaucoma and has developed computer software that has been adopted by
ophthalmologists nationwide.
Dr. Silverstone serves as the Director of Continuing
Medical Education for the American Society of Cataract
and Refractive Surgery and sits on the Governing Board of Directors of the
American Society of Ophthalmic
Administrators and the National Board of Certified Ophthalmic Executives.
He is also a fellow of the
American Academy of Ophthalmology, which has awarded him its Honor Award,
and serves on the
Executive Committee of the Connecticut Society of Eye Physicians. He is also
a member of the New
England Ophthalmologic Society, the Connecticut Glaucoma Society, the Connecticut
State Medical Society, the Association for Research in Vision & Ophthalmology
and the American Public Health Association.
|
